PDF(Pubmed)
Abstract：
Glioblastoma, the most common and aggressive form of primary brain tumor, poses significant challenges to patients, caregivers, and clinicians alike. Pediatric glioblastoma is a rare and aggressive brain tumor that presents unique challenges in treatment. It differs from its adult counterpart in terms of genetic and molecular characteristics. Its incidence is relatively low, but the prognosis remains grim due to its aggressive behavior. Diagnosis relies on imaging techniques and histopathological analysis. The rarity of the disease underscores the need for effective treatment strategies. In recent years, the quest to understand and manage pediatric glioblastoma has seen a significant shift towards unraveling the intricate landscape of biomarkers. Surgery remains a cornerstone of glioblastoma management, aiming to resect as much of the tumor as possible. Glioblastoma\'s infiltrative nature presents challenges in achieving a complete surgical resection. This comprehensive review delves into the realm of pediatric glioblastoma biomarkers, shedding light on their potential to not only revolutionize diagnostics but also shape therapeutic strategies. From personalized treatment selection to the development of targeted therapies, the potential impact of these biomarkers on clinical outcomes is undeniable. Moreover, this review underscores the substantial implications of biomarker-driven approaches for therapeutic interventions. All advancements in targeted therapies and immunotherapy hold promise for the treatment of pediatric glioblastoma. The genetic profiling of tumors allows for personalized approaches, potentially improving treatment efficacy. The ethical dilemmas surrounding pediatric cancer treatment, particularly balancing potential benefits with risks, are complex. Ongoing clinical trials and preclinical research suggest exciting avenues for future interventions.
摘要：
胶质母细胞瘤,最常见和侵袭性的原发性脑肿瘤，给患者带来了巨大的挑战，看护者,和临床医生一样。儿童胶质母细胞瘤是一种罕见的侵袭性脑肿瘤，在治疗中提出了独特的挑战。它在遗传和分子特征方面与成年对应物不同。其发病率相对较低,但由于其攻击行为，预后仍然严峻。诊断依赖于成像技术和组织病理学分析。这种疾病的罕见性强调了对有效治疗策略的需求。近年来,在对儿童胶质母细胞瘤的理解和治疗过程中,我们看到了一个重大转变,即揭示复杂的生物标志物.手术仍然是胶质母细胞瘤治疗的基石，目的是尽可能多地切除肿瘤。胶质母细胞瘤的浸润性在实现完整的手术切除方面提出了挑战。这篇全面的综述深入探讨了儿童胶质母细胞瘤生物标志物的领域，揭示了他们的潜力，不仅彻底改变了诊断，而且塑造了治疗策略。从个性化治疗选择到靶向治疗的发展,这些生物标志物对临床结局的潜在影响是不可否认的.此外，这篇综述强调了生物标志物驱动的治疗干预方法的重要意义.靶向治疗和免疫疗法的所有进展都有望治疗小儿胶质母细胞瘤。肿瘤的遗传分析允许个性化的方法，有可能提高治疗效果。围绕儿科癌症治疗的伦理困境，特别是在潜在利益与风险之间取得平衡，是复杂的。正在进行的临床试验和临床前研究为未来的干预提供了令人兴奋的途径。
